Jefferies Group Comments on Bristol-Myers Squibb Company’s FY2017 Earnings (NYSE:BMY)

Bristol-Myers Squibb Company (NYSE:BMY) – Equities researchers at Jefferies Group lifted their FY2017 earnings per share estimates for shares of Bristol-Myers Squibb Company in a report released on Wednesday. Jefferies Group analyst J. Holford now forecasts that the biopharmaceutical company will post earnings of $2.95 per share for the year, up from their previous forecast of $2.94. Jefferies Group currently has a “Buy” rating and a $63.00 target price on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb Company’s FY2018 earnings at $3.13 EPS, FY2020 earnings at $4.50 EPS and FY2021 earnings at $5.14 EPS.

Bristol-Myers Squibb Company (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 EPS for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.12. The business had revenue of $4.93 billion during the quarter, compared to the consensus estimate of $4.75 billion. Bristol-Myers Squibb Company had a return on equity of 31.86% and a net margin of 24.22%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the firm earned $0.74 earnings per share. WARNING: “Jefferies Group Comments on Bristol-Myers Squibb Company’s FY2017 Earnings (NYSE:BMY)” was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/jefferies-group-comments-on-bristol-myers-squibb-companys-fy2017-earnings-nysebmy-updated-updated-updated/1197032.html.

Other analysts have also recently issued reports about the stock. BidaskClub raised shares of Bristol-Myers Squibb Company from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb Company in a research note on Monday, June 26th. BMO Capital Markets cut shares of Bristol-Myers Squibb Company from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research note on Wednesday, May 3rd. Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb Company and gave the stock a “hold” rating in a research note on Monday. Finally, Vetr raised shares of Bristol-Myers Squibb Company from a “hold” rating to a “buy” rating and set a $61.64 price objective on the stock in a research note on Tuesday, March 21st. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Bristol-Myers Squibb Company presently has a consensus rating of “Hold” and an average target price of $62.54.

Bristol-Myers Squibb Company (NYSE BMY) traded up 0.29% during trading on Thursday, reaching $54.83. The company had a trading volume of 927,856 shares. The firm has a 50-day moving average price of $54.58 and a 200 day moving average price of $55.03. The stock has a market cap of $90.33 billion, a P/E ratio of 19.04 and a beta of 1.17. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $77.12.

A number of large investors have recently bought and sold shares of BMY. American National Bank raised its stake in shares of Bristol-Myers Squibb Company by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares during the last quarter. Welch Investments LLC raised its stake in shares of Bristol-Myers Squibb Company by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in shares of Bristol-Myers Squibb Company during the first quarter worth approximately $116,000. Blue Chip Partners Inc. raised its stake in shares of Bristol-Myers Squibb Company by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its stake in shares of Bristol-Myers Squibb Company by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. Institutional investors own 69.74% of the company’s stock.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th will be issued a $0.39 dividend. The ex-dividend date is Wednesday, July 5th. This represents a $1.56 annualized dividend and a yield of 2.85%. Bristol-Myers Squibb Company’s dividend payout ratio (DPR) is presently 54.17%.

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb Company (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.